Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2012

Open Access 01-12-2012 | Review

Novel CD20 monoclonal antibodies for lymphoma therapy

Authors: Shundong Cang, Nikhil Mukhi, Kemeng Wang, Delong Liu

Published in: Journal of Hematology & Oncology | Issue 1/2012

Login to get access

Abstract

Rituximab (RTX), a monoclonal antibody (mAb) against CD20, has been widely used for lymphoma therapy. RTX in combination with cyclophosphamide /doxorubicin /vincristine /prednisone (R-CHOP) remains the standard frontline regimen for diffuse large B-cell lymphoma. However, suboptimal response and /or resistance to rituximab have remained a challenge in the therapy of B-cell non-Hodgkin’s lymphoma (NHL). Novel agents are under active clinical trials. This review will summarize the latest development in new mAbs against CD20, which include second-generation mAbs, ofatumumab, veltuzumab (IMMU-106), ocrelizumab (PRO70769), and third-generation mAbs, AME-133v (ocaratuzumab), PRO131921 and GA101 (obinutumumab).
Appendix
Available only for authorised users
Literature
1.
Coiffier B: Rituximab in the treatment of diffuse large B-cell lymphomas. Semin Oncol. 2002, 29 (1 Suppl 2): 30-35.PubMedCrossRef
2.
Coiffier B: Rituximab in diffuse large B-cell lymphoma. Clin Adv Hematol Oncol. 2004, 2 (3): 156-157.PubMed
3.
Coiffier B: Rituximab and CHOP-like chemotherapy in good-prognosis diffuse large-B-cell lymphoma. Nature clinical practice Oncology. 2006, 3 (11): 594-595.PubMedCrossRef
4.
Coiffier B: Rituximab therapy in malignant lymphoma. Oncogene. 2007, 26 (25): 3603-3613. 10.1038/sj.onc.1210376.PubMedCrossRef
5.
Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002, 346 (4): 235-242. 10.1056/NEJMoa011795.PubMedCrossRef
6.
Mishima Y, Terui Y, Yokoyama M, Nishimura N, Sakajiri S, Ueda K, Kuboki Y, Nakano K, Suzuki K, Nara E: R-CHOP with dose-attenuated radiation therapy could induce good prognosis in gastric diffuse large B cell lymphoma. Experimental Hematology & Oncology. 2012, 1 (1): 30-10.1186/2162-3619-1-30.CrossRef
7.
Alduaij W, Illidge TM: The future of anti-CD20 monoclonal antibodies: are we making progress?. Blood. 2011, 117 (11): 2993-3001. 10.1182/blood-2010-07-298356.PubMedCrossRef
8.
Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, Shimada K, Chan CH, Tutt A, Beers SA: Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood. 2011, 117 (17): 4519-4529. 10.1182/blood-2010-07-296913.PubMedCentralPubMedCrossRef
9.
Tedder TF, Engel P: CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today. 1994, 15 (9): 450-454. 10.1016/0167-5699(94)90276-3.PubMedCrossRef
10.
Goldenberg DM, Morschhauser F, Wegener WA: Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leuk Lymphoma. 2010, 51 (5): 747-755. 10.3109/10428191003672123.PubMedCrossRef
11.
Uchiyama S, Suzuki Y, Otake K, Yokoyama M, Ohta M, Aikawa S, Komatsu M, Sawada T, Kagami Y, Morishima Y: Development of novel humanized anti-CD20 antibodies based on affinity constant and epitope. Cancer Sci. 2010, 101 (1): 201-209. 10.1111/j.1349-7006.2009.01392.x.PubMedCrossRef
12.
Robak T, Robak E: New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2011, 25 (1): 13-25. 10.2165/11539590-000000000-00000.CrossRef
13.
Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC: The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood. 2010, 116 (19): 3705-3714. 10.1182/blood-2010-04-001230.PubMedCentralPubMedCrossRef
14.
Honeychurch J, Alduaij W, Azizyan M, Cheadle EJ, Pelicano H, Ivanov A, Huang P, Cragg MS, Illidge TM: Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. Blood. 2012, 119 (15): 3523-3533. 10.1182/blood-2011-12-395541.PubMedCrossRef
15.
Czuczman MS, Gregory SA: The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leukemia & lymphoma. 2010, 51 (6): 983-994. 10.3109/10428191003717746.CrossRef
16.
Plosker GL, Figgitt DP: Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs. 2003, 63 (8): 803-843. 10.2165/00003495-200363080-00005.PubMedCrossRef
17.
Coiffier B, Pfreundschuh M, Stahel R, Vose J, Zinzani PL: Aggressive lymphoma: improving treatment outcome with rituximab. Anticancer Drugs. 2002, 13 (Suppl 2): S43-50.PubMedCrossRef
18.
Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani P: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006, 7 (5): 379-391. 10.1016/S1470-2045(06)70664-7.PubMedCrossRef
19.
Delaloye AB, Antonescu C, Louton T, Kuhlmann J, Hagenbeek A: Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial. J Nucl Med. 2009, 50 (11): 1837-1843. 10.2967/jnumed.109.067587.PubMedCrossRef
20.
Esmaeli B, McLaughlin P, Pro B, Samaniego F, Gayed I, Hagemeister F, Romaguera J, Cabanillas F, Neelapu SS, Banay R: Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Ann Oncol. 2009, 20 (4): 709-714. 10.1093/annonc/mdn692.PubMedCrossRef
21.
Friedberg JW, Fisher RI: Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma. Expert Rev Anticancer Ther. 2004, 4 (1): 18-26. 10.1586/14737140.4.1.18.PubMedCrossRef
22.
Buchegger F, Antonescu C, Helg C, Kosinski M, Prior JO, Delaloye AB, Press OW, Ketterer N: Six of 12 relapsed or refractory indolent lymphoma patients treated 10 years ago with 131I-tositumomab remain in complete remission. J Nucl Med. 2011, 52 (6): 896-900. 10.2967/jnumed.111.087460.PubMedCrossRef
23.
Corazzelli G, Frigeri F, Marcacci G, Capobianco G, Arcamone M, Becchimanzi C, Russo F, Pinto A: Rituximab plus gemcitabine, ifosfamide, oxaliplatin (R-GIFOX) as salvage therapy for recurrent Hodgkin lymphoma. ASCO Meeting Abstracts. 2009, 27 (15S): 8579-
24.
El Gnaoui T, Dupuis J, Belhadj K, Rahmouni A, Copie-Bergman C, Gaillard I, Divine M, Tabah-Fisch IM, Reyes F, Haioun C: Rituximab, gemcitabine and oxaliplatin (R-GEMOX): An effective regimen for relapsed and refractory B-cell lymphoma. ASCO Meeting Abstracts. 2006, 24 (18): 7562-
25.
Federico M, Luminari S, Dondi A, Sacchi S, Franco V, Pileri S, Lombardo M, Rossi G, Arcaini L, Chisesi T: R-CVP versus R-CHOP versus R-FM as first-line therapy for advanced-stage follicular lymphoma: Final results of FOLL05 trial from the Fondazione Italiana Linfomi (FIL). ASCO Meeting Abstracts. 2012, 30 (15): 8006-
26.
Recher C, Coiffier B, Haioun C, Molina TJ, Ferme C, Casasnovas O, Thieblemont C, Bosly A, Laurent G, Morschhauser F: Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet. 2011, 378 (9806): 1858-1867. 10.1016/S0140-6736(11)61040-4.PubMedCrossRef
27.
Reynolds C, Di Bella N, Lyons RM, Hyman W, Richards DA, Robbins GJ, Vellek M, Boehm KA, Zhan F, Asmar L: A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia. Investigational new drugs. 2012, 30 (3): 1232-1240. 10.1007/s10637-011-9737-y.PubMedCrossRef
28.
Rummel MJ, Niederle N, Maschmeyer G, Banat AG, von Gruenhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C: Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study. ASCO Meeting Abstracts. 2012, 30 (18): 3-
29.
30.
Tsimberidou AM, Wierda WG, Badoux X, Wen S, Plunkett W, O'Brien SM, Kipps TJ, Jones JA, Kantarjian H, Keating MJ: Evaluation of oxaliplatin, fludarabine, cytarabine, and rituximab (OFAR) combination therapy in aggressive chronic lymphocytic leukemia (CLL) and Richter's syndrome (RS). ASCO Meeting Abstracts. 2010, 28 (15): 6521-
31.
Tsimberidou AM, Wierda WG, Plunkett WK, O'Brien S, Lerner S, Smith SC, Kantarjian HM, Keating MJ: Phase I/II study of oxaliplatin, fludarabine, cytarabine, and rituximab in patients (OFAR2) with Richter's syndrome (RS), and relapsed or refractory B-cell chronic lymphocytic leukemia (CLL). ASCO Meeting Abstracts. 2009, 27 (15S): 7031-
32.
Baig NA, Taylor RP, Lindorfer MA, Church AK, Laplant BR, Pavey ES, Nowakowski GS, Zent CS: Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement. Leuk Lymphoma 2012:http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​22475085.​ 2012.
33.
Coiffier B, Lepretre S, Pedersen LM, Gadeberg O, Fredriksen H, van Oers MH, Wooldridge J, Kloczko J, Holowiecki J, Hellmann A: Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1–2 study. Blood. 2008, 111 (3): 1094-1100.PubMedCrossRef
34.
35.
Wierda WG, Kipps TJ, Durig J, Griskevicius L, Stilgenbauer S, Mayer J, Smolej L, Hess G, Griniute R, Hernandez-Ilizaliturri FJ: Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood. 2011, 117 (24): 6450-6458. 10.1182/blood-2010-12-323980.PubMedCrossRef
36.
Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M: Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010, 28 (10): 1749-1755. 10.1200/JCO.2009.25.3187.PubMedCrossRef
37.
Wierda WG, Padmanabhan S, Chan GW, Gupta IV, Lisby S, Osterborg A, Hx CDSI: Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood. 2011, 118 (19): 5126-5129. 10.1182/blood-2011-04-348656.PubMedCrossRef
38.
Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai PC, Gibbs JF, Deeb G, Czuczman MS: Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. Br J Haematol. 2012, 156 (4): 490-498. 10.1111/j.1365-2141.2011.08966.x.PubMedCrossRef
39.
Cheson BD: Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J Clin Oncol. 2010, 28 (21): 3525-3530. 10.1200/JCO.2010.27.9836.PubMedCrossRef
40.
Czuczman MS, Fayad L, Delwail V, Cartron G, Jacobsen E, Kuliczkowski K, Link BK, Pinter-Brown L, Radford J, Hellmann A: Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood. 2012, 119 (16): 3698-3704. 10.1182/blood-2011-09-378323.PubMedCrossRef
41.
Czuczman MS, Hess G, Gadeberg OV, Pedersen LM, Goldstein N, Gupta I, Jewell RC, Lin TS, Lisby S, Strange C: Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma. Br J Haematol. 2012, 157 (4): 438-445. 10.1111/j.1365-2141.2012.09086.x.PubMedCrossRef
42.
Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon MO, Coleman M, Schuster SJ, Dyer MJ, Horne H, Teoh N: Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol. 2009, 27 (20): 3346-3353. 10.1200/JCO.2008.19.9117.PubMedCrossRef
43.
Morschhauser F, Marlton P, Vitolo U, Linden O, Seymour JF, Crump M, Coiffier B, Foa R, Wassner E, Burger HU: Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann Oncol. 2010, 21 (9): 1870-1876. 10.1093/annonc/mdq027.PubMedCrossRef
44.
Stein R, Qu Z, Chen S, Rosario A, Shi V, Hayes M, Horak ID, Hansen HJ, Goldenberg DM: Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res. 2004, 10 (8): 2868-2878. 10.1158/1078-0432.CCR-03-0493.PubMedCrossRef
45.
Saleh MN, Liebman H, Bernstein ZP, Negrea OG, Bussel JB, Onyegbula AC, Farber CM, Abassi R, Cosgriff TM, Pennington K: Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab for Treatment of Relapsed Immune Thrombocytopenia (ITP). ASH Annual Meeting Abstracts. 2009, 114 (22): 1322-
46.
Tobinai K, Ogura M, Kobayashi Y, Uchida T, Watanabe T, Oyama T, Maruyama D, Suzuki T, Mori M, Kasai M: Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma. Cancer Sci. 2011, 102 (2): 432-438. 10.1111/j.1349-7006.2010.01809.x.PubMedCrossRef
47.
Forero-Torres A, de Vos S, Pohlman BL, Pashkevich M, Cronier DM, Dang NH, Carpenter SP, Allan BW, Nelson JG, Slapak CA: Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcgammaRIIIa-genotyped patients with previously treated follicular lymphoma. Clin Cancer Res. 2012, 18 (5): 1395-1403. 10.1158/1078-0432.CCR-11-0850.PubMedCrossRef
48.
Wayne JL, Ganjoo KN, Pohlman BL, De Vos S, Flinn IW, Dang NH, Mapara MY, Smith MR, O'Reilly AM, Marulappa SY: Efficacy of ocaratuzumab (AME-133v) in relapsed follicular lymphoma patients refractory to prior rituximab. ASCO Meeting Abstracts. 2012, 30 (15): 8081-
49.
Salles G, Morschhauser F, Lamy T, Milpied N, Thieblemont C, Tilly H, Bieska G, Asikanius E, Carlile D, Birkett J: Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood. 2012, 119 (22): 5126-5132. 10.1182/blood-2012-01-404368.PubMedCrossRef
50.
Carlile D, Meneses-Lorente G, Wassner-Fritsch E, Hourcade-Potelleret F, Wenger MK, Cartron G, Vitolo U, Radford J, Davies A, Morschhauser F: Pharmacokinetics of Obinutuzumab (GA101) in Patients with CD20+ Relapsed/Refractory Malignant Disease Receiving Concomitant Chemotherapy (Phase Ib Study BO21000). ASH Annual Meeting Abstracts. 2011, 118 (21): 3704-
51.
Friedberg JW, Vose J, Kahl BS, Brunvand M, Goy A, Kasamon Y, Brington B, Li J, Ho W, Cheson BD: A Phase I Study of PRO131921, a Novel Anti-CD20 Monoclonal Antibody in Patients with Relapsed/Refractory CD20+ Indolent NHL: Correlation Between Clinical Responses and AUC Pharmacokinetics. ASH Annual Meeting Abstracts. 2009, 114: 3472-
52.
Kahl BS, Cheson BD, Friedberg JW: Clinical Roundtable Monograph: current treatment options for NHL patients refractory to standard therapy: recent data in single-agent and combination therapy. Clin Adv Hematol Oncol. 2010, 8 (5): 1-16.PubMed
53.
van Meerten T, Hagenbeek A: CD20-targeted therapy: the next generation of antibodies. Seminars in hematology. 2010, 47 (2): 199-210. 10.1053/j.seminhematol.2010.01.007.PubMedCrossRef
54.
Friess T, Gerdes C, Nopora A, Patre M, Preiss S, van Puijenbroek E, Schuell C, Bauer S, Umana P, Klein C: GA101, a Novel Humanized Type II CD20 Antibody with Glycoengineered Fc and Enhanced Cell Death Induction, Mediates Superior Efficacy in a Variety of NHL Xenograft Models in Comparison to Rituximab. ASH Annual Meeting Abstracts. 2007, 110 (11): 2338-
55.
Heinrich D, Weinkauf M, Hutter G, Decheva K, Zimmermann Y, Hiddemann W, Dreyling MH: Differential Regulation Patterns of Anti-CD20 Antibodies GA101 and Rituximab in Mantle Cell Lymphoma. ASH Annual Meeting Abstracts. 2010, 116 (21): 1839-
56.
Herting F, Bader S, Umana P, Klein C: Enhanced Activity of GA101, a Novel Type II, Glycoengineered CD20 Antibody, In Combination with Bendamustine or Fludarabine, and with the Bcl-2 Family Inhibitors ABT-737 or ABT-263. ASH Annual Meeting Abstracts. 2010, 116 (21): 3915-
57.
Umana P, Ekkehard M, Peter B, Gabriele K, Ursula P, Suter T, Grau R, Schmidt C, Herter S, Gerdes C: GA101, a Novel Humanized Type II CD20 Antibody with Glycoengineered Fc and Enhanced Cell Death Induction, Exhibits Superior Anti-Tumor Efficacy and Superior Tissue B Cell Depletion In Vivo. ASH Annual Meeting Abstracts. 2007, 110 (11): 2348-
58.
Dalle S, Reslan L, Manquat SB, Herting F, Klein C, Umana P, Dumontet C: Compared Antitumor Activity of GA101 and Rituximab against the Human RL Follicular Lymphoma Xenografts in SCID Beige Mice. ASH Annual Meeting Abstracts. 2008, 112 (11): 1585-
59.
Ysebaert L, Laprevotte E, Klein C, Laurent G, Fournie J-J, Quillet-Mary A: Clinical and Biological Characteristics Associated with In Vitro Activity of Anti-CD20 Monoclonal Antibodies, Rituximab and GA101, Against Chronic Lymphocytic Leukemia Cells. ASH Annual Meeting Abstracts. 2010, 116 (21): 2459-
60.
Salles GA, Morschhauser F, Thieblemont C, Solal-Celigny P, Lamy T, Tilly H, Feugier P, Le Gouill S, Gyan E, Bouabdallah R: Efficacy and Safety of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma: Results From a Phase I/II Study (BO20999). ASH Annual Meeting Abstracts. 2011, 118 (21): 268-
61.
Meneses-Lorente G, Carlile D, Birkett J, Wenger MK, Cartron G, Morschhauser F, Salles GA: Pharmacokinetics of RO5072759 (GA101) In Patients with Relapsed/Refractory CD20+ Malignant Disease (Phase I/II Study BO20999). ASH Annual Meeting Abstracts. 2010, 116 (21): 1833-
62.
Sehn LH, Goy A, Offner FC, Martinelli G, Friedberg J, Lasserre SF, Fine G, Press OW: Randomized Phase II Trial Comparing GA101 (Obinutuzumab) with Rituximab in Patients with Relapsed CD20 Indolent B-Cell Non-Hodgkin Lymphoma: Preliminary Analysis of the GAUSS Study. ASH Annual Meeting Abstracts. 2011, 118 (21): 269-
63.
Batty N, Malouf G, Issa J: Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett. 2009, 280: 192-200. 10.1016/j.canlet.2009.03.013.PubMedCrossRef
64.
Brown JR, Sharman JP, Harb WA, Kelly KR, Schreeder MT, Sweetenham JW, Barr PM, Foran JM, Gabrilove JL, Kipps TJ: Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL). ASCO Meeting Abstracts. 2012, 30 (15): 8032-
65.
Budhu A, Ji J, Wang X: The clinical potential of microRNAs. Journal of Hematology & Oncology. 2010, 3 (1): 37-10.1186/1756-8722-3-37.CrossRef
66.
Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Sharman JP, Flinn IW, Grant BW, Heerema NA, Johnson AJ: The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): Interim results of a phase Ib/II study. ASCO Meeting Abstracts. 2012, 30 (15): 6507-
67.
Chanan-Khan A, Cheson B: Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol. 2008, 26: 1544-1552. 10.1200/JCO.2007.14.5367.PubMedCrossRef
68.
Chang JE, Kahl BS: Bendamustine: more ammunition in the battle against mantle cell lymphoma. Leuk Lymphoma. 2012, 53 (7): 1249-1250. 10.3109/10428194.2011.654342.PubMedCrossRef
69.
Elbaz H, Stueckle T, Tse W, Rojanasakul Y, Dinu C: Digitoxin and its analogs as novel cancer therapeutics. Experimental Hematology & Oncology. 2012, 1 (1): 4-10.1186/2162-3619-1-4.CrossRef
70.
Ge X, Wang X: Role of Wnt canonical pathway in hematological malignancies. Journal of Hematology & Oncology. 2010, 3 (1): 33-10.1186/1756-8722-3-33.CrossRef
71.
Johnson P: New targets for lymphoma treatment. Ann Oncol. 2008, 19 (4): 56-59.
72.
Patrick J, Yuan R, Cavalli F, Thomas W: Targeted therapy of lymphoma. J Hematol Oncol. 2010, 3: 45-10.1186/1756-8722-3-45.CrossRef
73.
Tan J, Cang S, Ma Y, Petrillo RL, Liu D: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol. 2010, 3: 5-10.1186/1756-8722-3-5.PubMedCentralPubMedCrossRef
74.
Turkson J: STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets. 2004, 8 (5): 409-422. 10.1517/14728222.8.5.409.PubMedCrossRef
75.
Wu ZL, Song YQ, Shi YF, Zhu J: High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma. J Hematol Oncol. 2011, 4 (1): 31-10.1186/1756-8722-4-31.PubMedCrossRef
76.
Yuan Y, Liao YM, Hsueh CT, Mirshahidi HR: Novel targeted therapeutics: inhibitors of MDM2. ALK and PARP. J Hematol Oncol. 2011, 4: 16-10.1186/1756-8722-4-16.PubMedCrossRef
77.
Adams J, Palombella V, Sausville E, Johnson J, Destree A, Lazarus D, Maas J, Pien C, Prakash S, Elliott P: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999, 59: 2615-2622.PubMed
78.
Belch A, Kouroukis C, Crump M, Sehn L, Gascoyne R, Klasa R, Powers J, Wright J, Eisenhauer E: A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol. 2007, 18: 116-121.PubMedCrossRef
79.
Blum K, Johnson J, Niedzwiecki D, Canellos G, Cheson B, Bartlett N: Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. Leuk Lymphoma. 2007, 48: 1313-1319. 10.1080/10428190701411458.PubMedCrossRef
80.
Coiffier B, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, Rule S, Teixeira A, Walewski J, de Vos S: Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol. 2011, 12 (8): 773-784. 10.1016/S1470-2045(11)70150-4.PubMedCrossRef
81.
Kahl B, Chang J, Eickhoff J, Gilbert L, Rogers E, Werndli J, Huie M, McFarland T, Volk M, Blank J: VcR-CVAD produces a high response rate in untreated mantle cell lymphoma: a phase II study from the Wisconsin Oncology Network. Blood. 2008, 112 (Suppl 1): 265-
82.
Mendler J, Kelly J, Voci S, Marquis D, Rich L, Rossi R, Bernstein S, Jordan C, Liesveld J, Fisher R: Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma. Ann Oncol. 2008, 19: 1759-1764. 10.1093/annonc/mdn365.PubMedCentralPubMedCrossRef
83.
Mitsiades C, Mitsiades N, Hideshima T, Richardson P, Anderson K: Proteasome inhibition as a new therapeutic principle in hematological malignancies. Curr Drug Targets. 2006, 7: 1341-1347. 10.2174/138945006778559247.PubMedCrossRef
84.
Trelle S, Sezer O, Naumann R, Rummel M, Keller U, Engert A, Borchmann P: Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018). Haematologica. 2007, 92: 568-569. 10.3324/haematol.10797.PubMedCrossRef
85.
Weigert O, Weidmann E, Mueck R, Bentz M, von Schilling C, Rohrberg R, Jentsch-Ullrich K, Hiddemann W, Dreyling M: A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study. Leuk Lymphoma. 2009, 50: 716-722. 10.1080/10428190902856790.PubMedCrossRef
86.
Habermann T, Lossos I, Justice G, Vose J, Wiernik P, McBride K, Wride K, Ervin-Haynes A, Takeshita K, Pietronigro D: Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol. 2009, 145: 344-349. 10.1111/j.1365-2141.2009.07626.x.PubMedCrossRef
87.
Altman J, Platanias L: Exploiting the mammalian target of rapamycin pathway in hematologic malignancies. Curr Opin Hematol. 2008, 15: 88-94. 10.1097/MOH.0b013e3282f3deaa.PubMedCrossRef
88.
Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, Laurell A, Offner F, Strahs A, Berkenblit A: Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009, 27: 3822-3829. 10.1200/JCO.2008.20.7977.PubMedCrossRef
89.
Johnston P, Inwards D, Colgan J, LaPlant B, Kabat B, Habermann T, Micallef I, Porrata L, Ansell S, Reeder C: A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010, 85: 320-324.PubMedCentralPubMed
90.
Jundt F, Raetzel N, Muller C, Calkhoven C, Kley K, Mathas S, Lietz A, Leutz A, Dorken B: A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein beta and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas. Blood. 2005, 106: 1801-1807. 10.1182/blood-2004-11-4513.PubMedCrossRef
91.
Teachey D, Grupp S, Brown V: Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol. 2009, 145: 569-580. 10.1111/j.1365-2141.2009.07657.x.PubMedCentralPubMedCrossRef
92.
Witzig T, Geyer S, Ghobrial I, Inwards D, Fonseca R, Kurtin P, Ansell S, Luyun R, Flynn P, Morton R: Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005, 23: 5347-5356. 10.1200/JCO.2005.13.466.PubMedCrossRef
93.
Yazbeck V, Buglio D, Georgakis G, Li Y, Iwado E, Romaguera J, Kondo S, Younes A: Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Exp Hematol. 2008, 36: 443-450. 10.1016/j.exphem.2007.12.008.PubMedCrossRef
94.
Yee K, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, Thomas D, Wierda W, Apostolidou E, Albitar M: Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2006, 12: 5165-5173. 10.1158/1078-0432.CCR-06-0764.PubMedCrossRef
95.
Chen Z, Han Z: STAT3: a critical transcription activator in angiogenesis. Med Res Rev. 2008, 28 (2): 185-200. 10.1002/med.20101.PubMedCrossRef
96.
Ding B, Yu J, Yu R, Mendez L, Shaknovich R, Zhang Y, Cattoretti G, Ye B: Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood. 2008, 111 (3): 1515-1523.PubMedCentralPubMedCrossRef
97.
98.
Al-Katib AM, Aboukameel A, Mohammad R, Bissery MC, Zuany-Amorim C: Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma. Clin Cancer Res. 2009, 15 (12): 4038-4045. 10.1158/1078-0432.CCR-08-2808.PubMedCrossRef
99.
Blanc V, Bousseau A, Caron A, Carrez C, Lutz RJ, Lambert JM: SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res. 2011, 17 (20): 6448-6458. 10.1158/1078-0432.CCR-11-0485.PubMedCrossRef
100.
Younes A, Kim S, Romaguera J, Copeland A, Farial Sde C, Kwak LW, Fayad L, Hagemeister F, Fanale M, Neelapu S: Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma. J Clin Oncol. 2012, 30 (22): 2776-2782. 10.1200/JCO.2011.39.4403.PubMedCrossRef
101.
Coiffier B, Morschhauser F, Dupuis J, Haioun C, Laine F, Houot R, Tilly H, Brehar O, Lambert JM, Fagniez N: Phase I study cohort evaluating an optimized administration schedule of SAR3419, an anti-CD19 DM4-loaded antibody drug conjugate (ADC), in patients (pts) with CD19 positive relapsed/refractory b-cell non-Hodgkin's lymphoma (NCT00796731). ASCO Meeting Abstracts. 2012, 30 (15): 8057-
102.
103.
Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M, York S, Ravandi F, Kwari M, Faderl S: Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. The lancet oncology. 2012, 13 (4): 403-411. 10.1016/S1470-2045(11)70386-2.PubMedCrossRef
104.
Hoelzer D: Anti-CD22 therapy in acute lymphoblastic leukaemia. The lancet oncology. 2012, 13 (4): 329-331. 10.1016/S1470-2045(12)70010-4.PubMedCrossRef
105.
Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R, Pastan I: Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012, 30 (15): 1822-1828. 10.1200/JCO.2011.38.1756.CrossRef
106.
Ogura M, Hatake K, Ando K, Tobinai K, Tokushige K, Ono C, Ishibashi T, Vandendries E: Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma. Cancer science. 2012, 103 (5): 933-938. 10.1111/j.1349-7006.2012.02241.x.PubMedCrossRef
107.
Sharkey RM, Govindan SV, Cardillo TM, Goldenberg DM: Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies. Molecular cancer therapeutics. 2012, 11 (1): 224-234. 10.1158/1535-7163.MCT-11-0632.PubMedCrossRef
108.
Ma H, Qazi S, Ozer Z, Gaynon P, Reaman GH, Uckun FM: CD22 Exon 12 deletion is a characteristic genetic defect of therapy-refractory clones in paediatric acute lymphoblastic leukaemia. British journal of haematology. 2012, 156 (1): 89-98. 10.1111/j.1365-2141.2011.08901.x.PubMedCrossRef
109.
de Vries JF, Zwaan CM, De Bie M, Voerman JS, den Boer ML, van Dongen JJ, van der Velden VH: The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2012, 26 (2): 255-264. 10.1038/leu.2011.206.CrossRef
110.
Chen WC, Sigal DS, Saven A, Paulson JC: Targeting B lymphoma with nanoparticles bearing glycan ligands of CD22. Leukemia & lymphoma. 2012, 53 (2): 208-210. 10.3109/10428194.2011.604755.CrossRef
111.
Biberacher V, Decker T, Oelsner M, Wagner M, Bogner C, Schmidt B, Kreitman RJ, Peschel C, Pastan I, Meyer Zum Buschenfelde C: The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-betaII depletion. Haematologica. 2012, 97 (5): 771-779. 10.3324/haematol.2011.049155.PubMedCentralPubMedCrossRef
112.
Sikder MA, Friedberg JW: Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma. Curr Hematol Malig Rep. 2008, 3 (4): 187-193. 10.1007/s11899-008-0027-5.PubMedCrossRef
113.
Gualberto A: Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies. Expert Opin Investig Drugs. 2012, 21 (2): 205-216. 10.1517/13543784.2011.641532.PubMedCrossRef
114.
115.
Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, Senter PD, Alley SC: Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res. 2010, 16 (3): 888-897. 10.1158/1078-0432.CCR-09-2069.PubMedCrossRef
116.
Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A: Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010, 363 (19): 1812-1821. 10.1056/NEJMoa1002965.PubMedCrossRef
Metadata
Title
Novel CD20 monoclonal antibodies for lymphoma therapy
Authors
Shundong Cang
Nikhil Mukhi
Kemeng Wang
Delong Liu
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2012
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-5-64

Other articles of this Issue 1/2012

Journal of Hematology & Oncology 1/2012 Go to the issue

Research

EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis

Research

Cytoreduction surgery reduces systemic myeloid suppressor cell populations and restores intratumoral immunotherapy effectiveness

Letter to the Editor

A novel monoclonal antibody of human stem cell factor inhibits umbilical cord blood stem cell ex vivo expansion

Research

Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study

Letter to the Editor

Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw

Rapid communication

Homozygous A polymorphism of the complement C1qA 276 correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits